F
Fabrice Barlesi
Researcher at Aix-Marseille University
Publications - 666
Citations - 36214
Fabrice Barlesi is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 64, co-authored 582 publications receiving 25403 citations. Previous affiliations of Fabrice Barlesi include Institut Gustave Roussy & Nord University.
Papers
More filters
Journal ArticleDOI
Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).
David Planchard,Harry J.M. Groen,Tae Min Kim,James R. Rigas,Pierre Jean Souquet,Christina S. Baik,Fabrice Barlesi,Julien Mazieres,Elisabeth Quoix,C. Martin Curtis,Bijoyesh Mookerjee,Arundathy N. Bartlett-Pandite,Christine Tucker,Anthony D'Amelio,Bruce E. Johnson +14 more
TL;DR: In this paper, the combination of D and T (DT) has demonstrated significant improvements in efficacy in terms of ORR in 78 BRAF V600E mut NSCLC pts, single agent D induced an overall response rate (ORR) of 32%.
Journal ArticleDOI
Video-assisted thoracoscopic management of recurrent primary spontaneous pneumothorax after prior talc pleurodesis: a feasible, safe and efficient treatment option
Christophe Doddoli,Fabrice Barlesi,Anne Fraticelli,Pascal Thomas,Philippe Astoul,Roger Giudicelli,Pierre Fuentes +6 more
TL;DR: Feasibility, safety and efficacy of VATS for management of recurrent primary spontaneous pneumothorax following thoracoscopic talc poudrage are strongly suggested.
Journal ArticleDOI
Lba39_prneratinib (n) with or without temsirolimus (tem) in patients (pts) with non-small cell lung cancer (nsclc) carrying her2 somatic mutations: an international randomized phase ii study
Benjamin Besse,J-C. Soria,B. Yao,Mark G. Kris,Bo H. Chao,Alexis B. Cortot,J. Mazieres,Mark A. Socinski,Leora Horn,S. Waqar,Fabrice Barlesi,Jhanelle E. Gray,D. Moro-Sibilot,Ana B. Oton,E. Quoix,Alshad S. Lalani,L. Mcculloch,Richard A. Bryce,Leena Gandhi +18 more
TL;DR: N + TEM met the efficacy criteria for stage 1 and has been expanded into stage 2, and Diarrhea was not a limiting toxicity with aggressive upfront management.
Journal ArticleDOI
Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis.
TL;DR: A non-small cell lung cancer patient treated with a carboplatin plus gemcitabine combination chemotherapy as first line followed by pemetrexed as second line therapy and presented with a radiation recall dermatitis is described.
Journal ArticleDOI
LBA1_PRPrimary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)
Martin Reck,Mark A. Socinski,Frederico Cappuzzo,Francisco Orlandi,D Stroyakovskii,Naoyuki Nogami,Delvys Rodriguez-Abreu,Denis Moro-Sibilot,Christian A. Thomas,Fabrice Barlesi,Gene Grant Finley,Claudia Kelsch,Anthony Lee,Shelley Coleman,Yijing Shen,Marcin Kowanetz,Ariel Lopez-Chavez,Alan Sandler,Robert M. Jotte +18 more